View source for Phase We measure escalation along with pharmacokinetic look at a pair of various schedules involving LY2334737 an oral gemcitabine prodrug within patients along with superior strong cancers
From EECH Central
You do not have permission to edit this page, for the following reasons:
You can view and copy the source of this page.